Kenya serosurvey finds 21 unrecognized mpox infections for every confirmed case

A serosurvey conducted along one of Kenya's busiest transport corridors suggests the country's mpox outbreak has spread far more widely than confirmed case counts show, with roughly 21 people carrying serologic evidence of infection for every one who had been formally diagnosed [s1]. The findings, published in the CDC journal Emerging Infectious Diseases, offer a rare measure of how much mpox transmission goes unrecognized [s1].

Kenya recorded its first mpox outbreak beginning in July 2024, driven by clade Ib — a newly recognized variant first identified in the Democratic Republic of the Congo that has since been reported in multiple countries inside and outside Africa [s1]. Between July 2024 and mid-August 2026, the country reported 1,260 laboratory-confirmed mpox cases, including 19 deaths [s1]. Confirmed cases, though, capture only the people who sought care, were tested, and had their results recorded — leaving open the question of how much milder or unreported infection sits beneath them.

What the blood samples showed

To quantify that hidden layer, researchers ran a cross-sectional serosurvey at eight clinics positioned along a major transportation corridor, enrolling adults between 29 September and 28 October 2025 [s1]. Participants completed a questionnaire and gave a blood sample tested with a serologic assay designed to distinguish likely monkeypox virus infection from orthopoxvirus vaccination [s1].

The assay's two-step design matters here: rather than simply flagging any orthopoxvirus antibody — a category that would sweep in anyone with residual smallpox-vaccine immunity — it was built to separate the signature of likely infection from that of vaccination, which is what lets the study speak to transmission rather than immunization history [s1].

Of 2,896 participants, 332 — 11.5% — were seropositive, and 82 of them, or 2.8%, were classified as having had a likely monkeypox virus infection [s1]. Only four participants reported a prior confirmed mpox case [s1]. Comparing those two figures — serologic evidence of infection against self-reported confirmed diagnosis — yielded a ratio of 21 to 1, the study's central estimate of undetected transmission [s1]. In other words, for every person who knew they had been diagnosed, the serology pointed to roughly 21 more who carried immunological footprints of infection without a confirmed diagnosis on record.

A large susceptible population

The second finding cuts the other way, and the authors treat it as equally important. Despite that evidence of undetected spread, most participants showed no serologic sign of prior orthopoxvirus exposure at all — neither past infection nor the residual immunity that older adults might retain from historical smallpox vaccination [s1]. That points to a large susceptible population still at risk, and the researchers frame it as support for additional vaccination and continued serosurveillance rather than a reason for reassurance [s1].

The two conclusions are not in tension. A corridor with substantial undetected transmission and a largely non-immune population is precisely the setting in which an outbreak can persist and reseed: enough circulation to keep the virus present, and enough susceptibility to let it keep finding new hosts. Transport corridors, with their high throughput of mobile people, are plausible arteries for exactly that kind of spread, which is partly why the survey was sited along one rather than in a single town.

The clade driving Kenya's outbreak sharpens the stakes. Clade Ib was only recently recognized, first identified in the Democratic Republic of the Congo before turning up in multiple countries within and beyond Africa [s1]. A newer variant moving through a mobile population with little pre-existing immunity is the combination public-health authorities most want early warning of, and routine case reporting — which depends on people falling ill enough to seek care and be tested — is poorly suited to catching the milder or unreported links in a transmission chain.

Serology has limits the authors are careful to mark. The assay estimates likely prior infection rather than confirming active disease, and a cross-sectional survey captures a moment, not a trajectory. The 21-to-1 ratio compares a laboratory signal against self-reported diagnoses, each measured imperfectly. But the direction of the gap is hard to argue with: confirmed case counts, in this corridor at least, substantially understate how many people the virus has reached. For a clade Ib outbreak that has already crossed multiple borders, a tool that reveals the scale of unrecognized transmission — and the size of the still-susceptible population — is the kind of data that shapes where vaccine and surveillance effort should go next [s1].

This article is informational and is not medical advice.